巨子生物2024年财报显示,其收入增长57.2%至55.39亿元,净利润增长42.2%至20.62亿元,连续六年实现营收增长。这主要得益于市场需求的加速释放和企业经营战略的成功实施。巨子生物通过丰富产品矩阵和全渠道布局,进一步巩固了其市场地位。核心品牌可复美在医疗器械系列和功效护肤系列中均表现优异,特别是在天猫伤口敷料类目和医用敷料热卖榜上蝉联第一。在线上,巨子生物利用电商平台和社交平台进行营销...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.